TY - JOUR
T1 - Triple antiviral therapy in HCV positive patients who failed prior combination therapy
AU - Fargion, Silvia
AU - Borzio, Mauro
AU - Maraschi, Alessandra
AU - Cargnel, Antonietta
AU - Bolognini, Giovanni
AU - Benetti, Gian Piero
AU - Fracanzani, Anna Ludovica
AU - Pinzello, Giovanni
AU - Vinci, Maria
AU - Croce, Guido
AU - Capretti, Andrea
AU - Giorni, Riccardo
AU - Pozzi, Massimo
AU - Redaelli, Alessandro
AU - Prada, Alberto
AU - Omazzi, Barbara
AU - Autolitano, Aldo
AU - Del Poggio, Paolo
PY - 2006/9/7
Y1 - 2006/9/7
N2 - Aim: To assess the efficacy of triple therapy (peginterferon or high dose standard interferon, plus ribavirin and amantadine) in nonresponders to prior combination therapy. Methods: A total of 196 patients were enrolled in a multicenter, open, randomized study. Patients were given 180 μg/wk of peginterferon-alpha-2a (40 kD) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d) for 48 wk (group A) or interferon-alpha-2a (6 MU/d for 4 wk, 3 MU/d for 20 wk, and 3 MU tiw for 24 wk) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d) for 48 wk (group B). Results: Overall sustained virologic response (SVR) was 26.6% (32.1% and 19.5% in group A and B, P = 0.057). Baseline ALT >120 UI/L (OR 2.4; 95% CI:1.11 to 5.20; P = 0.026) and HCV RNA negativity after 12 wk (OR 8.7; 95% CI: 3.87 to 19.74; P <0.0001) were independently associated with SVR. Therapy discontinuation occurred less frequently in patients treated with peginterferon than standard interferon (P = 0.036). Conclusion: More than 25% of nonresponders to combination therapy can eradicate HCV infection when retreated with triple therapy, especially if they have a high baseline ALT and are treated with pegylated interferon.
AB - Aim: To assess the efficacy of triple therapy (peginterferon or high dose standard interferon, plus ribavirin and amantadine) in nonresponders to prior combination therapy. Methods: A total of 196 patients were enrolled in a multicenter, open, randomized study. Patients were given 180 μg/wk of peginterferon-alpha-2a (40 kD) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d) for 48 wk (group A) or interferon-alpha-2a (6 MU/d for 4 wk, 3 MU/d for 20 wk, and 3 MU tiw for 24 wk) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d) for 48 wk (group B). Results: Overall sustained virologic response (SVR) was 26.6% (32.1% and 19.5% in group A and B, P = 0.057). Baseline ALT >120 UI/L (OR 2.4; 95% CI:1.11 to 5.20; P = 0.026) and HCV RNA negativity after 12 wk (OR 8.7; 95% CI: 3.87 to 19.74; P <0.0001) were independently associated with SVR. Therapy discontinuation occurred less frequently in patients treated with peginterferon than standard interferon (P = 0.036). Conclusion: More than 25% of nonresponders to combination therapy can eradicate HCV infection when retreated with triple therapy, especially if they have a high baseline ALT and are treated with pegylated interferon.
KW - Amantadine
KW - Hepatitis C
KW - Nonresponders
KW - Peginterferon
KW - Ribavirin
UR - http://www.scopus.com/inward/record.url?scp=33749415283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749415283&partnerID=8YFLogxK
M3 - Article
C2 - 16981257
AN - SCOPUS:33749415283
VL - 12
SP - 5293
EP - 5300
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 33
ER -